A Phase 1, Open-Label, Fixed-Sequence Crossover Study to Evaluate the Effect of a Strong Inhibitor of Cytochrome P450 2C19 on the Pharmacokinetics of Miricorilant in Healthy Subjects
Latest Information Update: 24 Mar 2023
At a glance
- Drugs Miricorilant (Primary) ; Fluvoxamine
- Indications Non-alcoholic steatohepatitis; Weight gain
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
Most Recent Events
- 20 Mar 2023 Status changed from recruiting to completed.
- 06 Feb 2023 New trial record